TG Therapeutics raises 2026 revenue guidance, outlines subcutaneous BRIUMVI timeline
TG Therapeutics lifted full-year 2026 global revenue guidance to about $1 billion and pointed to Phase 3 subcutaneous BRIUMVI data expected around year-end or early 2027.
SEC filing